Page last updated: 2024-12-05

4,4'-diaminodiphenylmethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7577
CHEMBL ID85728
CHEBI ID32506
SCHEMBL ID28001
MeSH IDM0054291

Synonyms (148)

Synonym
BIDD:ER0255
CHEMBL85728
p,p'-diaminodifenylmethan
p-toluidine, .alpha.-(p-aminophenyl)-
bis(4-aminophenyl)methane
nci-c54604
aniline,4'-methylenedi-
di(4-aminophenyl)methane
dianilinemethane
jeffamine ap-20
nsc-4709
101-77-9
diaminodiphenylmethane
tonox
nsc4709
4,4'-diaminodiphenylmethan
p,p'-methylenedianiline
p,p'-diaminodiphenylmethane
4,4'-methylenebis(aniline)
benzenamine,4'-methylenebis-
4-(4-aminobenzyl)aniline
4,4'-methylene(bisaniline)
4,4'-methylenedianiline
4,4'-diaminodiphenylmethane
bis-p-aminofenylmethan
4,4'-diphenylmethanediamine
ht 972
methylenebis(aniline)
di-(4-aminophenyl)methane
bis(p-aminophenyl)methane
dadpm
wln: zr d1r dz
methylenedianiline
epikure ddm
dianilinomethane
epicure ddm
SDCCGMLS-0066191.P001
OPREA1_406523
4,4'-methylenebis(benzeneamine)
alpha-(p-aminophenyl)-p-toluidine
aniline, 4,4'-methylenedi-
CHEBI:32506 ,
di-(p-aminophenyl)methane
bis-p-aminophenylmethane
4-[(4-aminophenyl)methyl]aniline
benzenamine, 4,4'-methylenebis-
inchi=1/c13h14n2/c14-12-5-1-10(2-6-12)9-11-3-7-13(15)8-4-11/h1-8h,9,14-15h
NCGC00091159-01
ccris 1010
hsdb 2541
methylenedianiline (van)
brn 0474706
sumicure m
un2651
p-toluidine, alpha-(p-aminophenyl)-
avaldite ht 972
4,4'-methylenebisbenzenamine
4,4'-dimethylenediamine
p,p'-diaminodifenylmethan [czech]
ancamine tl
araldite hardener 972
4,4'-diaminodiphenylmethan [german]
bis-p-aminofenylmethan [czech]
nsc 4709
4,4'-methylene dianiline
4,4'-methylenebisaniline
ai3-02615
einecs 202-974-4
curithane
NCGC00091159-02
4,4'-diaminodiphenylmethane, >=97.0% (gc)
AC-10921
AKOS000118778
STK988515
4,4'-methanediyldianiline
smr000019102
4-(4-aminobenzyl)phenylamine
MLS002303003
M0220
A800456
NCGC00091159-04
NCGC00091159-03
4,4-methylenedianiline
HMS3091M08
dtxsid6022422 ,
cas-101-77-9
tox21_300141
4,4'-diaminobiphenyl methane
tox21_201723
dtxcid402422
NCGC00259272-01
NCGC00254163-01
CCG-103567
bis-(4-aminophenyl)methane
4,4-diaminodiphenylmethane
4,4'-diaminodiphenyl methane
unii-gg5ll7obzc
gg5ll7obzc ,
4,4'-diaminodiphenyl methane [un2651] [poison]
ec 202-974-4
EPITOPE ID:116050
BBL022928
methylenebis(4-aminobenzene)
4,4 -methylenedianiline
4,4'-methylene-dianiline
di(para-aminophenyl)methane
SCHEMBL28001
4,4-diphenylmethane diamine
4,4'-diphenylmethane diamine
methylenedianiline-
4,4'-methylenedianiline [hsdb]
4,4'-methylenedianiline [iarc]
p,p'-diaminodiphenylmethane [mi]
4,4'-diaminodiphenylmethane (mda)
W-108903
dianiline, 4,4'-methylene-
4-(4-aminobenzyl)phenylamine #
un 2651
4,4'-methylenedibenzenamine
methylenebis[aniline]
bis(aminophenyl)methane
benzenamine,4-4'-methylenebis-
4,4'-methylenebis[aniline]
mfcd00007914
F0921-0063
sr-01000394053
SR-01000394053-1
4,4'-diaminodiphenylmethane, analytical standard
4,4'-diaminodiphenylmethane, certified reference material, tracecert(r)
EN300-19463
4, 4'-diphenylmethanediamine
p, p'-methylenedianiline
4,4'-methylenedi-aniline
4,4'-methylenebis-benzenamine
bis-p-aminofenylmethan(czech)
4-(4-aminobenzyl)phenylamine (acd/name 4.0)
4, 4'-methylenebis(aniline)
4, 4'-diaminodiphenylmethan(german)
p, p'-diaminodifenylmethan(czech)
1219795-26-2
VS-07280
Q229848
bis-(4-aminophenyl)methane 100 microg/ml in acetonitrile
aniline, 4,4'-methylenedi- (8ci)
YSWG197
4,4'-methylenedianiline--d8
PD074403
Z104473930

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The combination of autoclave sterilization and a PU produced from a larger-molecular-weight polyol is recommended to minimize the production of potentially toxic compounds."( The relative safety of gamma-ray, autoclave, and ethylene oxide gas sterilization of thermosetting polyurethane.
Shintani, H,
)
0.13
"Exposure to 4,4'-diaminodiphenylmethane (DAPM) has been linked to jaundice, toxic hepatitis, cholangitis, and cholestasis."( Evaluation of the gender differences in 4,4'-methylenedianiline toxicity, distribution, and effects on biliary parameters.
Dugas, TR; Kanz, MF; Liu, H; Santa Cruz, V, 2001
)
0.69
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" A physiologically based pharmacokinetic (PBPK) model was developed to estimate the absorption, distribution, metabolism, and excretion of MDA in patients exposed to MDA leached from the potting materials of hemodialyzers."( Pharmacokinetic modeling of 4,4'-methylenedianiline released from reused polyurethane dialyzer potting materials.
Do Luu, HM; Hutter, JC, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" The extent of binding to rat hemoglobin of MDA was determined by dosing animals with the 14C-ring-labeled compound."( Monitoring exposure to 4,4'-methylenedianiline by the gas chromatography-mass spectrometry determination of adducts to hemoglobin.
Bailey, E; Bird, I; Brooks, AG; Farmer, PB; Street, B, 1990
)
0.28
" The dose-response relationships for hemoglobin adducts and urine metabolites were non-linear over this dose range."( Hemoglobin adducts and urine metabolites of 4,4'-methylenedianiline after 4,4'-methylenediphenyl diisocyanate exposure of rats.
Heinrich, U; Henschler, D; Hoymann, HG; Sabbioni, G; Schütze, D; Sepai, O, 1995
)
0.29
" It was possible to release MDA and MDA-d4 from DNA of rats dosed with MDA and/or MDA-d4 and from the synthesized adducts using strong base hydrolysis."( Synthesis and quantification of DNA adducts of 4,4'-methylenedianiline.
Sabbioni, G; Sagelsdorff, P; Schütze, D; Sepai, O,
)
0.13
" With all other chemicals, the dose-response curves for DNA fragmentation and viability were mirror images."( Investigation of the induction of DNA double-strand breaks by methylenediphenyl-4-4'-diisocyanate in cultured human lung epithelial cells.
Gahlmann, R; Lutz, WK; Vamvakas, S; Vock, EH, 1998
)
0.3
" In female rats, however, biliary constituents showed either minimal dose-response effects (glucose), were increased equivalently at both doses (Pi), or were not altered by DAPM treatment (GGT)."( Evaluation of the gender differences in 4,4'-methylenedianiline toxicity, distribution, and effects on biliary parameters.
Dugas, TR; Kanz, MF; Liu, H; Santa Cruz, V, 2001
)
0.31
" Based on the results of dose-response studies ranging up to 150 mg/kg MDA administered by intragastric gavage, the effect of a moderately hepatotoxic dose (37."( 4,4'-methylenedianiline-induced hepatotoxicity is modified by N-acetyltransferase 2 (NAT2) acetylator polymorphism in the rat.
Arteel, GE; Doll, MA; Hein, DW; Lambert, JC; Walraven, JM; Zhang, X, 2006
)
0.33
" Additional groups were dosed by gavage and intraperitoneal injection."( Analysis of biomarkers in rats and dogs exposed to polymeric methylenediphenyl diisocyanate (pMDI) and its glutathione adduct.
Brown, WE; Hext, P; Leibold, E; Leng, G; Pauluhn, J, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.31620.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency35.48130.004023.8416100.0000AID485290
AR proteinHomo sapiens (human)Potency60.68070.000221.22318,912.5098AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency47.05790.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency46.34650.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency21.87240.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency60.13730.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency49.54780.000229.305416,493.5996AID1259244; AID1259248; AID743075; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency48.20040.001024.504861.6448AID743212
aryl hydrocarbon receptorHomo sapiens (human)Potency48.83280.000723.06741,258.9301AID743085; AID743122
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency67.47510.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency57.62340.000627.21521,122.0200AID651741; AID743202
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency60.13730.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency75.70830.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency60.13730.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency31.62281.995325.532750.1187AID624287
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (129)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID446992Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 300 mg/kg, ip after 0.5 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446997Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 0.5 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446993Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, ip after 4 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446991Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 100 mg/kg, ip after 0.5 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446996Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 0.25 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID1653411Anti-leprotic activity against Mycobacterium leprae infected in BALB/c mouse assessed as time delay in bacterial multiplication in footpad at 0.008 g/100g of diet administered via feed starting 60 or 75 day post infection up to 90 days by Shepard's kineti2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID447143Neurotoxicity in CF1 albino mouse at 100 mg/kg, ip by rotarod test2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID168112Carcinogenic activity after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID446999Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 2 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID446994Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 100 mg/kg, ip after 4 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID446990Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, ip after 0.5 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID447000Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 4 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID307626Solubility in water
AID446995Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electric shock-induced seizure at 300 mg/kg, ip after 4 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID577835Antiprion activity in human transmissible spongiform encephalopathies agent Fukuoka-1 prion infected GT1-7 cells assessed as proteinase K-resistant proteins at 10 uM after 3 days Western blotting analysis relative to control2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Synthesis of GN8 derivatives and evaluation of their antiprion activity in TSE-infected cells.
AID167951Carcinogenic activity on ear duct after oral administration of the compound; - denotes non carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID307625Partition coefficient, log P of the compound
AID446998Anticonvulsant activity in Sprague-Dawley rat assessed as inhibition of maximal electric shock-induced seizure at 30 mg/kg, po after 1 hrs2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity.
AID1281296Induction of cell differentiation in human HL60 at 10 uM after 3 days by leishmans staining based microscopic analysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.
AID167940Tested for carcinogenic activity on breast after oral administration of the compound; - denotes non carcinogenic activity.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168088Compound was tested for carcinogenic activity on liver after oral administration of the compound; na denotes data not available.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID1281292Induction of cell differentiation in human HL60 cells assessed as increase in differentiation index at 10 uM measured after 3 days by NBT/MTT assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents.
AID167928Carcinogenic activity on all sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168101Carcinogenic activity on mixed data after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (175)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (23.43)18.7374
1990's51 (29.14)18.2507
2000's38 (21.71)29.6817
2010's35 (20.00)24.3611
2020's10 (5.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.68 (24.57)
Research Supply Index5.24 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index58.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.13%)6.00%
Case Studies17 (9.04%)4.05%
Observational0 (0.00%)0.25%
Other167 (88.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]